Literature DB >> 35285488

Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.

Helena J Janse van Rensburg1, Pavlina Spiliopoulou1, Lillian L Siu1.   

Abstract

Circulating biomarkers have emerged as valuable surrogates for evaluating disease states in solid malignancies. Their relative ease of access and rapid turnover has bolstered clinical applications in monitoring treatment efficacy and cancer progression. In this review, the roles of various circulating biomarkers in monitoring treatment response are described. Non-specific markers of disease burden, tumor markers (eg CA 125, CEA, PSA, etc.), circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays are highlighted. Specifically, the discovery of each of these markers is reviewed, with examples illustrating their use in influencing treatment decisions, and barriers to their application noted where these exist. Finally, opportunities for future work using these circulating biomarkers are discussed.
© The Author(s) 2022. Published by Oxford University Press.

Entities:  

Keywords:  biomarker; ctDNA; exosomes; metabolomics; treatment response; tumor marker

Mesh：

Substances：

Year:  2022        PMID： 35285488      PMCID： PMC9074993          DOI： 10.1093/oncolo/oyac047

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159            Impact factor:   5.837


  147 in total

1.  Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  H Tilly; M Dreyling
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy.

Authors:  Dima El-Sharkawi; Suprotim Basu; Charina Ocampo; Wendi Qian; Shirley D'Sa; Peter J Hoskin; Kirit M Ardeshna
Journal:  Leuk Lymphoma       Date:  2012-05-22

Review 3.  Emerging applications of metabolomics in drug discovery and precision medicine.

Authors:  David S Wishart
Journal:  Nat Rev Drug Discov       Date:  2016-03-11       Impact factor: 84.694

4.  Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.

Authors:  G J S Rustin
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

5.  Turnover of mouse intestinal brush border membrane proteins and enzymes in organ culture. A direct evaluation from studies on the evolution of enzyme activities during the culture.

Authors:  A Berteloot; J G Chabot; J S Hugon
Journal:  Biochim Biophys Acta       Date:  1981-12-18

6.  Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.

Authors:  Friederike Egberts; Eva Maria Kotthoff; Sascha Gerdes; Jan Hendrik Egberts; Michael Weichenthal; Axel Hauschild
Journal:  Eur J Cancer       Date:  2011-09-12       Impact factor: 9.162

7.  Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.

Authors:  Isabelle Iwanicki-Caron; Frédéric Di Fiore; Isabelle Roque; Emilie Astruc; Monica Stetiu; Aude Duclos; David Tougeron; Sandrine Saillard; Sébastien Thureau; Jacques Benichou; Bernard Paillot; Jean Pierre Basuyau; Pierre Michel
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

8.  Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients.

Authors:  Maura Campitelli; Emmanuelle Jeannot; Martine Peter; Emmanuelle Lappartient; Stéphanie Saada; Anne de la Rochefordière; Virginie Fourchotte; Séverine Alran; Peter Petrow; Paul Cottu; Jean-Yves Pierga; Olivier Lantz; Jérôme Couturier; Xavier Sastre-Garau
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

9.  An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer.

Authors:  Zhenya Jia; Jian Zhang; Zhonghua Wang; Biyun Wang; Leiping Wang; Jun Cao; Zhonghua Tao; Xichun Hu
Journal:  Oncotarget       Date:  2018-01-13

10.  Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers.

Authors:  Sameh Daher; Yaacov R Lawrence; Elizabeth Dudnik; Ekaterina Hanovich; Damien Urban; Nir Peled; Rossie Navon; Raya Leibowitz; Ariel Hammerman; Erez Battat; Teodor Gottfried; Amir Onn; Jair Bar
Journal:  Front Oncol       Date:  2021-07-21       Impact factor: 6.244
View more
  1 in total

1.  Exercise as cancer treatment: A clinical oncology framework for exercise oncology research.

Authors:  Kerry S Courneya; Christopher M Booth
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.